Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies

Charli E Harlow(University of Exeter), Timothy M. Frayling(University of Geneva), Dawn Waterworth(GlaxoSmithKline (United States)), Niek Verweij(Regeneron (United States)), Amy S. Etheridge(University of North Carolina at Chapel Hill), Dereje D. Jima(North Carolina State University), Fred A. Wright(North Carolina State University), Pim van der Harst(Utrecht University), Rosemary A. Bamford(University of Exeter), Asami Oguro‐Ando(University of Exeter), Andrew R. Wood(University of Exeter), Pranav S. Garimella, Harold Snieder(University Medical Center Groningen), Hampton L. Leonard(National Institutes of Health), Josan Gandawijaya(University of Exeter), Paul J. Gallins(University of Miami), Federico Innocenti(AbbVie (United States)), Jessica Tyrrell(The University of Sydney), Luigi Ferrucci(National Institute on Aging), Peter J. van der Most(University Medical Center Groningen), Robin N. Beaumont(University of Exeter), Toshiko Tanaka(MedStar Health), Emily-Rose Martin(University of Exeter), Eleanor M. Simonsick(National Institutes of Health), Stefania Bandinelli(Spanish National Cancer Research Centre), Yi‐Hui Zhou(North Carolina State University), Dena G. Hernandez, Peter van der Meer(University Medical Center Groningen), Audrey Y. Chu(University of Helsinki), Vickas V. Patel(University of Pennsylvania), Eric J. Shiroma(National Heart Lung and Blood Institute), Mike A. Nalls(National Institutes of Health), Ron T. Gansevoort(University Medical Center Groningen)
The American Journal of Human Genetics
September 1, 2022
Cited by 13


Related Papers